GURUFOCUS.COM » STOCK LIST » Healthcare » Medical Diagnostics & Research » Biodesix Inc (NAS:BDSX) » Definitions » Beneish M-Score

Biodesix (Biodesix) Beneish M-Score : -3.51 (As of May. 05, 2024)


View and export this data going back to 2020. Start your Free Trial

What is Biodesix Beneish M-Score?

The zones of discrimination for M-Score is as such:

An M-Score of equal or less than -1.78 suggests that the company is unlikely to be a manipulator.
An M-Score of greater than -1.78 signals that the company is likely to be a manipulator.

Good Sign:

Beneish M-Score -3.51 no higher than -1.78, which implies that the company is unlikely to be a manipulator.

The historical rank and industry rank for Biodesix's Beneish M-Score or its related term are showing as below:

BDSX' s Beneish M-Score Range Over the Past 10 Years
Min: -3.86   Med: -3.51   Max: -2.89
Current: -3.51

During the past 6 years, the highest Beneish M-Score of Biodesix was -2.89. The lowest was -3.86. And the median was -3.51.


Biodesix Beneish M-Score Historical Data

The historical data trend for Biodesix's Beneish M-Score can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Biodesix Beneish M-Score Chart

Biodesix Annual Data
Trend Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
Beneish M-Score
Get a 7-Day Free Trial - - -3.86 -2.89 -3.51

Biodesix Quarterly Data
Dec18 Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23
Beneish M-Score Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only -2.89 -3.68 -4.77 -4.27 -3.51

Competitive Comparison of Biodesix's Beneish M-Score

For the Diagnostics & Research subindustry, Biodesix's Beneish M-Score, along with its competitors' market caps and Beneish M-Score data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Biodesix's Beneish M-Score Distribution in the Medical Diagnostics & Research Industry

For the Medical Diagnostics & Research industry and Healthcare sector, Biodesix's Beneish M-Score distribution charts can be found below:

* The bar in red indicates where Biodesix's Beneish M-Score falls into.



Biodesix Beneish M-Score Calculation

The M-score was created by Professor Messod Beneish. Instead of measuring the bankruptcy risk (Altman Z-Score) or business trend (Piotroski F-Score), M-score can be used to detect the risk of earnings manipulation. This is the original research paper on M-score.

The M-Score Variables:

The M-score of Biodesix for today is based on a combination of the following eight different indices:

M=-4.84+0.92 * DSRI+0.528 * GMI+0.404 * AQI+0.892 * SGI+0.115 * DEPI
=-4.84+0.92 * 1.1802+0.528 * 0.8566+0.404 * 0.9086+0.892 * 1.2846+0.115 * 2.5413
-0.172 * SGAI+4.679 * TATA-0.327 * LVGI
-0.172 * 0.8535+4.679 * -0.282191-0.327 * 1.6563
=-3.51

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

This Year (Dec23) TTM:Last Year (Dec22) TTM:
Total Receivables was $7.68 Mil.
Revenue was 14.668 + 13.491 + 11.872 + 9.056 = $49.09 Mil.
Gross Profit was 11.294 + 10.262 + 8.634 + 5.887 = $36.08 Mil.
Total Current Assets was $39.68 Mil.
Total Assets was $99.10 Mil.
Property, Plant and Equipment(Net PPE) was $29.61 Mil.
Depreciation, Depletion and Amortization(DDA) was $5.51 Mil.
Selling, General, & Admin. Expense(SGA) was $67.39 Mil.
Total Current Liabilities was $33.42 Mil.
Long-Term Debt & Capital Lease Obligation was $60.39 Mil.
Net Income was -9.139 + -10.949 + -13.356 + -18.702 = $-52.15 Mil.
Non Operating Income was 0.036 + -1.391 + 0.001 + 0.042 = $-1.31 Mil.
Cash Flow from Operations was -12.283 + -3.838 + 0.937 + -7.686 = $-22.87 Mil.
Total Receivables was $5.07 Mil.
Revenue was 9.607 + 11.107 + 10.95 + 6.548 = $38.21 Mil.
Gross Profit was 6.301 + 7.474 + 6.97 + 3.313 = $24.06 Mil.
Total Current Assets was $53.33 Mil.
Total Assets was $92.91 Mil.
Property, Plant and Equipment(Net PPE) was $8.82 Mil.
Depreciation, Depletion and Amortization(DDA) was $5.84 Mil.
Selling, General, & Admin. Expense(SGA) was $61.46 Mil.
Total Current Liabilities was $22.84 Mil.
Long-Term Debt & Capital Lease Obligation was $30.26 Mil.




1. DSRI = Days Sales in Receivables Index

Measured as the ratio of Revenue in Total Receivables in year t to year t-1.

A large increase in DSR could be indicative of revenue inflation.

DSRI=(Receivables_t / Revenue_t) / (Receivables_t-1 / Revenue_t-1)
=(7.679 / 49.087) / (5.065 / 38.212)
=0.156437 / 0.13255
=1.1802

2. GMI = Gross Margin Index

Measured as the ratio of gross margin in year t-1 to gross margin in year t.

Gross margin has deteriorated when this index is above 1. A firm with poorer prospects is more likely to manipulate earnings.

GMI=GrossMargin_t-1 / GrossMargin_t
=(GrossProfit_t-1 / Revenue_t-1) / (GrossProfit_t / Revenue_t)
=(24.058 / 38.212) / (36.077 / 49.087)
=0.629593 / 0.73496
=0.8566

3. AQI = Asset Quality Index

AQI is the ratio of asset quality in year t to year t-1.

Asset quality is measured as the ratio of non-current assets other than Property, Plant and Equipment to Total Assets.

AQI=(1 - (CurrentAssets_t + PPE_t) / TotalAssets_t) / (1 - (CurrentAssets_t-1 + PPE_t-1) / TotalAssets_t-1)
=(1 - (39.683 + 29.612) / 99.096) / (1 - (53.334 + 8.821) / 92.906)
=0.300729 / 0.33099
=0.9086

4. SGI = Sales Growth Index

Ratio of Revenue in year t to sales in year t-1.

Sales growth is not itself a measure of manipulation. However, growth companies are likely to find themselves under pressure to manipulate in order to keep up appearances.

SGI=Sales_t / Sales_t-1
=Revenue_t / Revenue_t-1
=49.087 / 38.212
=1.2846

5. DEPI = Depreciation Index

Measured as the ratio of the rate of Depreciation, Depletion and Amortization in year t-1 to the corresponding rate in year t.

DEPI greater than 1 indicates that assets are being depreciated at a slower rate. This suggests that the firm might be revising useful asset life assumptions upwards, or adopting a new method that is income friendly.

DEPI=(Depreciation_t-1 / (Depreciaton_t-1 + PPE_t-1)) / (Depreciation_t / (Depreciaton_t + PPE_t))
=(5.844 / (5.844 + 8.821)) / (5.507 / (5.507 + 29.612))
=0.3985 / 0.15681
=2.5413

Note: If the Depreciation, Depletion and Amortization data is not available, we assume that the depreciation rate is constant and set the Depreciation Index to 1.

6. SGAI = Sales, General and Administrative expenses Index

The ratio of Selling, General, & Admin. Expense(SGA) to Sales in year t relative to year t-1.

SGA expenses index > 1 means that the company is becoming less efficient in generate sales.

SGAI=(SGA_t / Sales_t) / (SGA_t-1 /Sales_t-1)
=(67.387 / 49.087) / (61.462 / 38.212)
=1.372807 / 1.608448
=0.8535

7. LVGI = Leverage Index

The ratio of total debt to Total Assets in year t relative to yeat t-1.

An LVGI > 1 indicates an increase in leverage

LVGI=((LTD_t + CurrentLiabilities_t) / TotalAssets_t) / ((LTD_t-1 + CurrentLiabilities_t-1) / TotalAssets_t-1)
=((60.388 + 33.416) / 99.096) / ((30.258 + 22.839) / 92.906)
=0.946597 / 0.571513
=1.6563

8. TATA = Total Accruals to Total Assets

Total accruals calculated as the change in working capital accounts other than cash less depreciation.

TATA=(IncomefromContinuingOperations_t - CashFlowsfromOperations_t) / TotalAssets_t
=(NetIncome_t - NonOperatingIncome_t - CashFlowsfromOperations_t) / TotalAssets_t
=(-52.146 - -1.312 - -22.87) / 99.096
=-0.282191

An M-Score of equal or less than -1.78 suggests that the company is unlikely to be a manipulator. An M-Score of greater than -1.78 signals that the company is likely to be a manipulator.

Biodesix has a M-score of -3.51 suggests that the company is unlikely to be a manipulator.


Biodesix Beneish M-Score Related Terms

Thank you for viewing the detailed overview of Biodesix's Beneish M-Score provided by GuruFocus.com. Please click on the following links to see related term pages.


Biodesix (Biodesix) Business Description

Traded in Other Exchanges
N/A
Address
2970 Wilderness Place, Suite 100, Boulder, CO, USA, 80301
Biodesix Inc is a data-driven diagnostic solutions company. Its artificial intelligence-based platform helps to discover, develop, and commercialize solutions for clinical unmet needs, with a focus on lung disease. It provides biopharmaceutical companies with services that include diagnostic research, clinical trial testing, and the discovery, development, and commercialization of companion diagnostics. The revenue is derived from two sources, providing diagnostic testing services associated with blood-based lung and Coronavirus Disease 2019 (COVID-19) tests; and providing biopharmaceutical companies with services generally provided outside the clinical setting and governed by individual contracts with third parties as well as development and commercialization of companion diagnostics.
Executives
Scott Hutton director, officer: President & CEO 9965 FEDERAL DRIVE, COLORADO SPRINGS CO 80921
Kieran O'kane officer: Chief Commercial Officer 2970 WILDERNESS PLACE, SUITE 100, BOULDER CO 80301
Gary Anthony Pestano officer: Chief Development Officer 2970 WILDERNESS PLACE, SUITE 100, BOULDER CO 80301
Robin Harper Cowie officer: CFO, Sec'y & Treasurer 2970 WILDERNESS PLACE, SUITE 100, BOULDER CO 80301
Chris Vazquez officer: Chief Accounting Officer 2970 WILDERNESS PLACE, SUITE 100, BOULDER CO 80301
Jack W Schuler director, 10 percent owner 100 N. FIELD DRIVE, SUITE 360, LAKE FOREST IL 60045
Jon Faiz Kayyem director 5964 LA PLACE COURT, CARLSBAD CA 92008
Kennedy Lawrence T. Jr director, 10 percent owner C/O WESTWOOD MANAGEMENT, 1700 MADISON ROAD, SUITE 200, CINCINNATI OH 45206
Ryan H Siurek officer: Chief Accounting Officer 6200 SPRINT PARKWAY, OVERLAND PARK KS 66251
John Patience director, 10 percent owner, other: Chairman 28161 N. KEITH DRIVE, LAKE FOREST IL 60045
Matthew Strobeck director C/O METABOLIX, INC., 21 ERIE STREET, CAMBRIDGE MA 02139
Charles M Watts director 3950 SOUTH COUNTRY CLUB, SUITE 470, TUCSON AZ 85714
Hany Massarany director 1910 INNOVATION PARK DR, TUCSON AZ 85737
Georgantas Robert William Iii director, officer: SVP, Rsrch & Trans'l Science 2970 WILDERNESS PLACE, SUITE 100, BOULDER CO 80301
Jean M. Franchi director C/O DIMENSION THERAPEUTICS, INC., 840 MEMORIAL DRIVE, CAMBRIDGE MA 02139

Biodesix (Biodesix) Headlines

From GuruFocus